Here’s Why Ariad Pharmaceuticals Was Absolutely Pummeled in September | Traderszone

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 10 October, 2015 by The TZ Newswire Staff

Here’s Why Ariad Pharmaceuticals Was Absolutely Pummeled in September

Ariad shareholders learned the hard way in September that betting on a buyout is not a smart investing strategy.

See also
- Next Article What Does FICO Stand for?
- Previous Article NewsWatch: Chinese all-cash buyers of U.S. homes have tripled since 2005
Editorial Calender

October 2015

M T W T F S S

1 2 3 4

5 6 7 8 9 10 11

12 13 14 15 16 17 18

19 20 21 22 23 24 25

26 27 28 29 30 31

« Sep Nov »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar